NCT00483067View on ClinicalTrials.gov

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 1998

Primary Completion Date

March 31, 2006

Study Completion Date

July 31, 2008

Conditions
Leukemia
Interventions
DRUG

2-CdA

12 mg/m\^2/day by vein (IV) Continuous Infusion x 5 Days

DRUG

Ara-C

1 gm/m\^2/day IV Over 2 Hours x 5 Days

DRUG

G-CSF (Granulocyte colony-stimulating factor)

5 mcg/kg/day given under the skin (subcutaneously) starting Day 9

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00483067 - 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) | Biotech Hunter | Biotech Hunter